New hope for lymphoma patients: experimental combo targets hard-to-treat cancer
NCT ID NCT07562022
First seen May 04, 2026 · Last updated May 13, 2026 · Updated 2 times
Summary
This study tests a new drug called SCTB35 combined with lenalidomide in people whose follicular lymphoma has returned or stopped responding to prior treatment. About 93 adults aged 18-80 will be randomly assigned to receive either the new combination or the standard rituximab-plus-lenalidomide regimen. The goal is to see if the new combo improves cancer control and is safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA ( FL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
Conditions
Explore the condition pages connected to this study.